孕酮预防早产:《孤儿药法案》的缺陷与意外后果
本文评述17α-羟孕酮己酸酯(17α-hydroxyprogesterone caproate)预防早产的现状,指出路易斯安那州2013至2016年通过多层面举措使医疗补助计划中符合条件的高危孕妇接受该疗法的比例增加3.5倍,但绝大多数符合条件者仍未获得治疗。作者认为美国食品药品监督管理局批准后该药价格高昂加剧了获取障碍,全国可能因此损失近6万例本可避免的早产,并揭示《孤儿药法案》的缺陷与意外后果。
要点
- 17α-羟孕酮己酸酯对高危孕妇自发性早产具有已知疗效,但美国绝大多数符合条件者仍未接受治疗。
- 路易斯安那州2013至2016年医疗补助计划中符合条件高危孕妇接受17α-羟孕酮己酸酯的比例增加3.5倍。
- 作者认为该药获批后价格高昂加剧获取障碍,全国可能因此损失近6万例本可避免的早产。
核心结论
- 作者认为,自美国食品药品监督管理局批准以来孕酮的高价格不必要地复杂化了获取途径,美国可能因此损失近6万例本可避免的早产。
- 作者认为17α-羟孕酮己酸酯的经历凸显了高价格对获取途径的持久障碍,并有助于揭示《孤儿药法案》的缺陷与意外后果。
- 作者认为该案例并非例外,而是美国药品市场垄断定价的常见产物,现有法律无意中助长了这一现象,代价是可负担性和患者获取。
研究设计与样本
- 本文为当前评论(Current Commentary)类文章,论述孤儿药审批及生产商提价的历史、药价与早产种族和族裔差异的相互作用,以及路易斯安那州改善孕酮覆盖的努力。
主要发现
- 路易斯安那州卫生部门通过多层面举措改善17α-羟孕酮己酸酯的获取,使医疗补助计划中符合条件高危孕妇接受该疗法的比例在2013年至2016年间增加3.5倍。
- 尽管路易斯安那州取得进展,绝大多数符合条件人群仍未接受17α-羟孕酮己酸酯。
- 作者提出美国可能因孕酮高价格损失近6万例本可避免的早产。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preterm birth is a problem of major public health significance that continues to plague our country despite the existence of a therapy, 17α-hydroxyprogesterone caproate, with known efficacy in reducing the risk of spontaneous preterm birth among high-risk women. Over the past several years, the Louisiana Department of Health has undertaken a robust, multifaceted initiative to improve access to 17α-hydroxyprogesterone caproate, which resulted in a 3.5-fold increase in the percentage of eligible high-risk pregnant women in the Medicaid program who received the therapy between 2013 and 2016. Yet despite Louisiana's progress, the vast majority of the eligible population still fails to receive 17α-hydroxyprogesterone caproate. In this Current Commentary, we argue that the high price of progesterone since U.S. Food and Drug Administration approval has unnecessarily complicated access, and our nation has potentially suffered nearly 60,000 avoidable premature births as a consequence. We present the history of the orphan drug approval and manufacturer-imposed price increase for injectable progesterone, the interplay between the drug's high price and the persistence of racial and ethnic disparities in preterm birth, which are particularly germane in Louisiana, and Louisiana's broad-reaching efforts to improve progesterone coverage. The story of 17α-hydroxyprogesterone caproate highlights the durable barriers that high prices place in the way of access and helps illuminate the shortcomings and unintended consequences of the Orphan Drug Act. This case, however, is not an outlier; it is the far-too-common product of monopoly pricing in the U.S. pharmaceutical market, inadvertently bolstered by existing law, at the expense of affordability and patient access.
引用
- Gee RE, Kuy S, Karas LO, et al. Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act. Obstet Gynecol. 2017. PMID: 29112651. doi:10.1097/AOG.0000000000002308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。